{"schema_version":"secwatch.filing_event.v1","accession":"0001720580-26-000060","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2026-09-28T12:15:31+00:00","discovered_at":"2026-09-28T12:20:38.539143+00:00","generated_at":"2026-10-12T13:31:09.939765+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adicet prula-cel Phase 1: 50% CRR in lupus nephritis at 12 months, 54% DORIS remission; pivotal study to start Q4 2026","bullets":["22 efficacy-evaluable patients (16 lupus nephritis, 6 extra-renal SLE) with 6-21 months follow-up; 13 patients had at least 12 months of follow-up.","At 12 months, 50% of evaluable LN patients achieved a complete renal response and 54% achieved DORIS remission; all 12-month responses ongoing at 12-21 months except 1 patient.","Safety: no CRS greater than Grade 2, Grade 1/2 CRS in 25%, no DLTs, IEC-HS or ICANS; infections in 54% (Grade 3+ 8.3%); no GvHD; FDA-aligned profile supports outpatient dosing.","All patients discontinued immunosuppressants and all but one tapered steroids to 5 mg or less prednisone equivalent; 22/22 achieved undetectable CD19+ B cells with naive-dominant reconstitution.","FDA-aligned single-arm pivotal LN study (inadequate response to 2+ immunosuppressants; primary endpoint CRR at 12 months) start-up in Q4 2026; data updates H1 2027 (SSc) and mid-2027 (LN/SLE)."],"urls":{"canonical":"https://secwatch.observer/filing/0001720580-26-000060","json":"https://secwatch.observer/filing/0001720580-26-000060.json","markdown":"https://secwatch.observer/filing/0001720580-26-000060.md","text":"https://secwatch.observer/filing/0001720580-26-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000060/0001720580-26-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000060/acet-20260928.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:31:09.939765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}